Eisai Executive and Leadership Team

Toshio Imai, the President & Chief Executive Officer & Scientific Chief & Officer at Eisai, directs the overarching corporate strategy and scientific research initiatives. This leadership position involves guiding the company's global pharmaceutical development pipeline, with a particular emphasis on treatments for Alzheimer's disease, dementia, epilepsy, and various cancers. Overseeing the integration of scientific discovery with commercialization, Toshio Imai ensures that Eisai's therapeutic innovations translate into tangible patient benefits. The role demands a deep understanding of complex biological mechanisms and market dynamics to drive the development of novel medicines. By championing cutting-edge research, the President & Chief Executive Officer & Scientific Chief & Officer spearheads efforts to tackle challenging diseases and improve global health outcomes. This executive's vision shapes Eisai's long-term trajectory in the competitive pharmaceutical landscape, focusing on delivering breakthrough therapies.

Shaji Procida, the President & Chief Operating Officer at Eisai, executes the company's operational framework and day-to-day business functions. This critical role involves optimizing internal processes, managing global supply chains for pharmaceutical products, and ensuring efficient production of medications like Aricept, Methycobal, and Fycompa. Overseeing manufacturing, quality control, and distribution networks, Shaji Procida drives operational excellence across Eisai's diverse portfolio, which includes treatments for pain, insomnia, and autoimmune diseases. The President & Chief Operating Officer ensures seamless integration of research findings into scalable manufacturing, supporting the company's mission to deliver vital medicines worldwide. By streamlining operations, this executive enhances Eisai's capacity to meet patient demand and maintain high standards of product integrity. Shaji Procida's leadership ensures the robust delivery of Eisai's therapeutic solutions to markets across the globe.

Cynthia Schwalm, the President at Eisai, spearheads strategic initiatives and market expansion, particularly within key geographic regions. This leadership function involves driving the commercial success of Eisai's pharmaceutical offerings, including innovative treatments for thyroid cancer, renal cell carcinoma, and breast cancer. Overseeing sales, marketing, and business development efforts, Cynthia Schwalm ensures that Eisai's therapeutic agents reach patients effectively. The President collaborates closely with research and development teams to align market needs with scientific advancements, fostering growth in areas such as oncology and neurology. By cultivating strategic partnerships and expanding market access, Schwalm strengthens Eisai's global presence and impact. This executive's focus on market penetration and patient access is crucial for delivering Eisai's life-changing medications to those in need.

Michael De, the President, Eisai Machinery (USA) at Eisai, directs the specialized operations of the company's machinery division within the United States. This role focuses on the development, manufacturing, and distribution of advanced pharmaceutical machinery, supporting Eisai's broader production capabilities. Overseeing technological innovation and operational efficiency in this sector, Michael De ensures that Eisai Machinery provides state-of-the-art equipment for pharmaceutical production. The President, Eisai Machinery (USA) plays a key part in maintaining the high standards required for drug manufacturing equipment, contributing to Eisai's overall product quality and reliability. By driving advancements in machinery technology, De supports the company's mission to deliver essential medicines. This executive's leadership ensures the division's contribution to Eisai's global operational strength.